Tag: Biocad

BIOCAD is Russia’s leading innovative biotechnology company which combines a world-class research and development center, ultra-modern pharmaceutical and biotechnology manufacturing facilities, and pre-clinical and clinical research infrastructure compliant with international standards.

BIOCAD is one of the few world’s full-cycle drug development and manufacturing companies, doing everything from new molecules discovery and genetic engineering to large-scale commercial manufacturing and marketing support. BIOCAD’s medicines are used to treat the most complex health conditions, such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders.

The company employs about 1000 people, 300 out of them scientists and researchers. In 2014 BIOCAD’s sales tripled and reached $200 million, while total amount of long-term international contracts exceeded half a billion US dollars. BIOCAD has subsidiaries in the US, Brazil, China, India, Singapore, and other countries.

BIOCAD has established a wide international presence – through a network of its subsidiaries and partnerships – in Belarus, Ukraine, Brazil, India, China and the United States. BIOCAD’s international strategy is to reinforce its own market leadership position in Russia while entering new markets, thus leveraging and balancing R&D, sales, procurement and logistic synergies across several continents. Every subsidiary or a partner company successfully combines R&D, market evaluation and business development activities, and provides access to talents, innovations and market opportunities of the region.

First Russian Original Therapeutic Monoclonal Antibody is Registered

Biotechnology company BIOCAD registered its original interleukin-17 inhibitor (anti-IL-17) for the treatment of moderate to severe plaque psoriasis. Development and clinical studies of the new drug Ef...

Biocad intends to develop and bring to the Chinese market six drugs

Russian biotech company Biocad plans to develop and bring to the Chinese market at least six drugs in partnership with the Chinese holding Shanghai Pharmaceuticals.

BIOCAD and SPH agreed to start pharmaceutical production in China

BIOCAD and Shanghai Pharmaceuticals Holding used Eastern Economic Forum 2018 to sign a memorandum of understanding regarding the establishment of two joint ventures.

BIOCAD and Gem-Standard increase financing for projects at St Petersburg SEZ

On August 30, the Expert Council of Special Economic Zone (SEZ) 'St. Petersburg' approved the amendments for two ongoing projects of the existing SEZ residents - CJSC Biocad and Gem-Standard LLC.

BIOCAD started to set up equipment at its new manufacturing facility

The BIOCAD strategic investment project is entering the final stage of implementation - installation of equipment began in the building intended for manufacturing.

BIOCAD’s biosimilar of darbepoetin alfa will be available at the end of 2018

BIOCAD announced the completion of clinical trials for the first Russian-made biosimilar of darbepoetinalfa (BCD-066), which was designed to treat anemia related to chronic kidney disease or cancer.

Bioengineering and Biomedicine program opens under the BIOCAD’s patronage

A new Bioengineering and Biomedicine Master's program opens under the patronage of BIOCAD, a biotech company, in Saint-Petersburg State Chemical Pharmaceutical University of the Russian Ministry of Health.

Russian biosimilar of rituximab was approved for registration in Cuba

Cuban Ministry of Health (CECMED) approved for registration the biosimilar of rituximab manufactured by BIOCAD, a Russian biotech company. Supplies of this drug to Cuba are scheduled for the end of 2018.

BIOCAD will invest $26 million in infrastructure for gene therapies development

The agreements on collaboration and joint research in the area of adoptive immunotherapy were signed between V.A. Almazov National Medical Research Center and BIOCAD, a biotech company, on May 24, 2018.

Pharmaceutical companies are actively investing in St. Petersburg SEZ

st petersburg sez
Since the beginning of 2018, the residents of St. Petersburg Special Economic Zone (SEZ) have invested 1.787 billion rubles in their projects. Over the same period of last year, the residents invested 1.537 billion rubles.

Biocad signs export contracts worth about $850 million

In 2018, Biocad, a pharmaceutical company, expects that its exports outside CIS will reach 1 billion rubles, said Alexey Torgov, Deputy General Director, on April 11 at a pharmaceutical forum held in St. Petersburg.

NatiVita plans to set up R&D centers in Belarus and Saint Petersburg

test tubes
Plans have been made to set up centers for developing personified vaccines in Belarus and Saint Petersburg, according to Aleksei Sychev, Chairman of the Board of Directors of the Belarusian pharmaceutical company NatiVita.

BIOCAD opens new laboratory to develop biologics

BIOCAD, a biotech company, has opened a new lab in one of its R&D centers located in the village of Lyubuchany, Moscow region, where it plans to use unique technology to develop biological drugs.

BIOCAD leads the sales of anti-tumor drugs

For January-December 2017, BIOCAD retains, for the second year in a row, the leadership in the segment of public budget procurement (by taking into account the data on all drugs) in ruble terms and in final prices.

Russia registers its first domestically manufactured biosimilar of infliximab

The Russian Ministry of Health has registered BCD-055, the first Russian-made biosimilar of infliximab developed by BIOCAD, a biotech company. BIOCAD was developing the local biosimilar of infliximab since 2013.

Russian biosimilar of adalimumab fully confirmed its equivalence

BIOСAD has successfully completed the main stage of clinical trials for the Russian biosimilar of adalimumab, a drug for the treatment of autoimmune and chronic inflammatory diseases